SecBot SecBot
Biotech Drug Report Generated Jul 10, 2026

Tagrisso

AZN·ASTRAZENECA PLC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Approved and marketed since 2015 (first FDA approval Nov 2015)
Why 4/10
Tagrisso is already approved and commercially established with no pending PDUFA or pivotal readout in the next ~12 months. Its next binary catalyst was the Sept 2024 Stage III NSCLC approval, which has passed. As a mature blockbuster at a diversified pharma, there is no single hard dated event that would drive a dramatic share-price move, capping impactScore at 4 per the rubric.
Actionable Insight NEUTRAL

Tagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.

Price Chart

Loading chart...

Executive Summary

Tagrisso (osimertinib) is AstraZeneca's top-selling drug, generating ~$7.3 billion in 2025 revenue (~12% of AZN's total). It is a third-generation EGFR TKI approved across multiple lines of EGFR-mutated non-small cell lung cancer (NSCLC), from adjuvant early-stage through first-line metastatic and Stage III unresectable after chemoradiation. The drug faces a credible competitive threat from Johnson & Johnson's Rybrevant (amivantamab)/Lazcluze (lazertinib) combo, which showed superior overall survival in first-line NSCLC in the MARIPOSA trial. Patent protection extends to ~2032-2038. A US appeals court recently (July 2026) upheld a ruling in AZN's favor in a patent dispute with Pfizer. For a non-medical investor, Tagrisso is the mature, slow-growth cash cow of AZN's oncology portfolio, important but not a binary catalyst.

How It Works

Tagrisso is a targeted cancer pill (a third-generation EGFR inhibitor) that blocks a specific mutated protein on lung cancer cells, telling them to stop growing and dividing. It is designed to work against common EGFR mutations (exon 19 deletion, L858R) and also the T790M resistance mutation that develops after older EGFR inhibitors stop working.

Trial Status

Tagrisso is FDA-approved across multiple NSCLC indications: first-line metastatic (2018 full approval), adjuvant early-stage (ADAURA), with chemotherapy first-line (FLAURA2, Feb 2024), and unresectable Stage III after chemoradiation (LAURA, Sept 2024). The LAURA trial's overall survival data are still maturing. Multiple Phase 2/3 combination trials (with savolitinib, chemotherapy, novel agents) are ongoing.

The Two-Sided Case

▲ Bull Case6
Tagrisso is AZN's #1 drug at $7.3B in FY2025 revenue (+10% CER growth), with strong demand across all approved indications (source: AstraZeneca FY2025 results)
Label expanded significantly in 2024 (FLAURA2 + chemo in Feb, LAURA Stage III unresectable in Sept), opening new patient populations and extending the growth runway
Patent portfolio protects to ~2032-2038; a US appeals court (July 2026) upheld AZN's win against Pfizer's patent challenge, removing a key overhang (source: Reuters, July 9, 2026)
Analyst consensus is Strong Buy (29 buy/strong buy vs 4 hold/2 sell) with mean price target $221.09, implying ~29% upside from ~$171.61
LAURA Phase III data showed Tagrisso reduced risk of progression or death by 84% in Stage III unresectable NSCLC vs placebo (source: AstraZeneca press release, Feb 2024)
Tagrisso plus chemo demonstrated median overall survival of nearly 4 years in FLAURA2, the longest ever reported in a global Phase III trial in EGFR-mutated advanced NSCLC (source: AstraZeneca press release, 2025)
▼ Bear Case5
J&J's Rybrevant (amivantamab)/Lazcluze (lazertinib) combo beat Tagrisso on overall survival in first-line EGFR-mutated NSCLC (MARIPOSA trial), posing the most credible threat to Tagrisso's first-line standard-of-care position (source: pharmaphorum, appliedclinicaltrialsonline)
Several institutional funds exited AZN positions in Q1 2026, including Wells Fargo (-100%, 3.1M shares) and Scotia Capital (-100%, 461K shares), per latest 13F filings
Quant signals show a low composite score (-40) and factor alignment of just 1, indicating weak momentum/valuation signals relative to peers
Generic/patent cliff risk remains, earliest generic entry estimated around July 2032 per DrugPatentWatch, and 63% of patent challenges favor the generic challenger historically (source: Drugs.com, DrugPatentWatch)
Tagrisso's growth is decelerating as the drug matures; FY2025 revenue grew ~10% CER vs prior-year double-digit growth rates, and competition from J&J's combo could pressure first-line share further

Upcoming Catalysts

  • LAURA Phase III overall survival (OS) readout, the trial is continuing to assess OS as a secondary endpoint; mature data could drive further label momentum
  • Quarterly earnings reports, Tagrisso sales growth trajectory vs J&J competitive impact is a key investor focus
  • Potential new combination trial readouts (savolitinib + osimertinib for MET-amplified NSCLC)
  • Patent litigation developments, any future Paragraph IV challenges from generic manufacturers

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ASTRAZENECA PLC COURT-RULING AZN ·Originating report

Sources · 15

Hover a chip for the title
1 fda.gov2 astrazeneca.com3 astrazeneca.com4 astrazeneca.com5 astrazeneca.com6 reuters.com7 pharmaphorum.com8 insights.citeline.com9 drugs.com10 drugpatentwatch.com11 astrazeneca.com12 news.syenza.com13 tagrissohcp.com14 hlth.com15 pdf.marketpublishers.com